REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the comparative efficacy of caloric restriction versus liraglutide treatment in managing obesity and prediabetes, emphasizing the importance of personalized intervention strategies.
Back to Research Library
glucagon-like peptide-1 receptor agonistliraglutide

Highlighting the comparative efficacy of caloric restriction versus liraglutide treatment in managing obesity and prediabetes, emphasizing the importance of personalized intervention strategies.

May 17, 2026
Share

Source Paper

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J et al.Diabetes, obesity & metabolism2023
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Caloric Restriction Outperforms Liraglutide in Weight Loss and Body Composition Improvement for Prediabetes Patients

Published: May 17, 2026 | Source: Diabetes, obesity & metabolism (2023) | Category: glucagon-like peptide-1 receptor agonist, liraglutide

Overview

A recent study published in Diabetes, Obesity & Metabolism compared the effects of caloric restriction and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on weight loss and body composition improvement among adults with obesity and prediabetes. The findings suggest that while both methods are beneficial for cardiometabolic risk reduction, caloric restriction leads to greater weight loss and more favorable changes in body fat distribution.

Study Background

Previous research has highlighted the benefits of GLP-1RAs like liraglutide in managing type 2 diabetes and obesity. However, questions remain about their comparative efficacy against traditional dietary interventions such as caloric restriction. This study aimed to address these gaps by comparing weight loss outcomes between caloric restriction and liraglutide treatment.

What the Research Found

The randomized trial involved 88 adults with obesity and prediabetes who were assigned to one of three groups: caloric restriction (-390 kcal/day), liraglutide (1.8 mg/day), or sitagliptin (a DPP-4 inhibitor used as a control). After 14 weeks, the study found that:

  • Weight Loss: Caloric restriction led to weight loss in 44% of participants, compared to 22% for liraglutide and only 5% for sitagliptin.
  • Body Composition: The ratio of fat to lean mass decreased by 6.5% with caloric restriction versus 2.2% with liraglutide, while there was no change in the sitagliptin group.
  • Visceral Fat Reduction: Caloric restriction resulted in a 9.5% reduction in visceral fat compared to 4.8% for liraglutide and none for sitagliptin.

Additionally, spontaneous dietary changes in the caloric restriction group led to improved insulin resistance scores (HOMA-IR).

What This Means for Peptide Users

For individuals with obesity and prediabetes, this study highlights that while GLP-1RAs like liraglutide offer significant benefits, caloric restriction may be more effective in promoting weight loss and improving body composition. However, the choice of intervention should consider individual preferences and risk factors.

Limitations and Caveats

The study's small sample size (88 participants) limits its generalizability to broader populations. Additionally, the short duration (14 weeks) means long-term effects remain uncertain. These limitations underscore the need for further research to confirm these findings in larger and more diverse groups over extended periods.

How This Compares to Previous Research

While previous studies have shown positive outcomes with GLP-1RAs like liraglutide, this study provides a direct comparison against caloric restriction. Other research has also indicated the benefits of dietary interventions for improving metabolic health, aligning with these findings but emphasizing the need for personalized approaches.

Our Analysis

PeptideVault views this study as valuable in providing evidence-based insights into weight management strategies for prediabetes patients. The comparative analysis offers a nuanced understanding of how different treatments can impact body composition and cardiometabolic risk factors differently. However, the limitations noted highlight the importance of cautious interpretation until further validation is achieved.

Key Takeaways

  • Caloric Restriction Outperforms: Caloric restriction leads to greater weight loss and more favorable changes in body fat distribution compared to liraglutide.
  • Personalized Interventions: The study supports a personalized approach to treatment, considering individual preferences and risk factors for optimal outcomes.
  • Further Research Needed: Larger studies over longer durations are required to confirm these findings and explore long-term effects.

Original Source

Citation: Silver Heidi J, Olson Dianna, Mayfield Dustin et al. (2023). Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.15113

Access: https://pubmed.ncbi.nlm.nih.gov/37188932/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimetics

Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.

GLP-1 receptor agonistsexenatideliraglutide

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

semaglutideliraglutide

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.